Measles and rubella elimination: communicating the importance of vaccination
The goal of this project is to support EU Member States in their fight against measles and rubella. This report should enable Member States to engage in effective, evidence-based risk communication.
The goal of this project is to support EU Member States in their fight against measles and rubella. More specifically, this project aims to:
- dispel the myths about measles vaccination;
- offer scientific, evidence-based corrections of misperceptions on measles
- inform about rubella infections in pregnancy; and
- discuss the risks and benefits of vaccination against rubella for women of childbearing age.
This report should enable Member States to engage in effective, evidence-based risk communication. Information on measles and rubella is presented in a modular fashion, so it can be easily used in customised leaflets, flyers, or web pages. The facts presented in this report are intended to lower the barriers to measles and rubella vaccination and raise awareness for congenital rubella syndrome (CRS), including awareness for ante-natal screenings and post-partum vaccination.
COVID-19 vaccination and prioritisation strategies in the EU/EEA
22 Dec 2020 - This document builds on a previously published ECDC report, ‘Key aspects regarding the introduction and prioritisation of COVID-19 vaccination in the EU/EEA and the UK’ . By using mathematical modelling, this document provides EU/EEA countries with information on factors that may affect the choice of COVID-19 vaccination
Overview of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA and the UK
2 Dec 2020 - This document outlines the initial developments in EU/EEA member states and the UK regarding vaccine deployment plans and national vaccination strategies for COVID-19 vaccines, including interim considerations for priority groups, evidence to be considered for the prioritisation of target groups, logistical considerations and monitoring systems for post-marketing surveillance (e.g. vaccine coverage, safety, effectiveness and acceptance).
Key aspects regarding the introduction and prioritisation of COVID-19 vaccination in the EU/EEA and the UK
26 Oct 2020 - This document provides an overview of the key aspects related to the initial phases following the introduction of one or more COVID-19 vaccines in the European Union and European Economic Area (EU/EEA) and the United Kingdom (UK). The aim is to support but not define EU policy on COVID-19 vaccination.